share_log

Earnings Call Summary | Organogenesis(ORGO.US) Q1 2024 Earnings Conference

Earnings Call Summary | Organogenesis(ORGO.US) Q1 2024 Earnings Conference

财报电话会议摘要 | Organogenesis (ORGO.US) 2024 年第一季度财报会议
moomoo AI ·  05/10 11:56  · 电话会议

The following is a summary of the Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript:

以下是Organogenesis Holdings, Inc.(ORGO)2024年第一季度财报电话会议记录摘要:

Financial Performance:

财务业绩:

  • Organogenesis Holdings reported Q1 net revenue of $110 million, an increase of 2% from the previous year.

  • Advanced Wound Care net revenue was $103.9 million, a growth of 3%.

  • Net revenue for Surgical and Sports Medicine products saw a slight decrease of 9%, bringing it to $6.1 million.

  • Gross profit increased to $81.3 million, which is equivalent to 73.9% of net revenue.

  • Both operating loss and net loss for the first quarter reduced to $3.9 million and $2.1 million respectively.

  • Organogenesis Holdings公布的第一季度净收入为1.1亿美元,比上年增长2%。

  • 高级伤口护理净收入为1.039亿美元,增长3%。

  • 外科和运动医学产品的净收入略有下降9%,达到610万美元。

  • 毛利增至8,130万美元,相当于净收入的73.9%。

  • 第一季度的营业亏损和净亏损分别减少至390万美元和210万美元。

Business Progress:

业务进展:

  • Significant advancements were seen in the Phase III clinical trial for ReNu, a product designed to manage knee osteoarthritis symptoms.

  • The trial data exhibited a significant reduction in knee OA pain, improved patient functioning, and successful safety profiling.

  • A strategic increase in engagement with customers led to revitalizing existing customers and driving overall growth.

  • Two of the company's products, Apligraf and Affinity, made it to the proposed LCD covered list for Medicare reimbursement.

  • Organogenesis continues to develop clinical validation data to secure coverage for other products.

  • Financial guidance for 2024 projects net revenue between $445 million and $470 million, indicative of a 3% to 9% increase in year-over-year growth.

  • The company views the bundled payment system as an essential move to control and manage the market effectively. The implementation may only take place in 2026 or later.

  • For the product ReNu, ORGO expects to complete data analysis by the end of May and have a meeting with FDA in early August. They anticipate revealing the results by September.

  • Depending on the requirement of one or two studies for approval, they aim at BLA submission in Q2 of '26 (two studies) or '25 (one study), with a corresponding anticipated approval and commercialization in Q2 of '27 or '26 respectively.

  • ReNU的III期临床试验取得了重大进展,该产品旨在控制膝盖骨关节炎症状。

  • 试验数据显示,膝关节 OA 疼痛显著减轻,患者功能得到改善,安全性分析成功。

  • 战略性地提高了与客户的互动,从而振兴了现有客户并推动了整体增长。

  • 该公司的两款产品Apligraf和Affinity已进入拟议的LCD医疗保险报销保障清单。

  • Organogenesis继续开发临床验证数据,以确保其他产品的覆盖范围。

  • 2024年的财务指导预计净收入在4.45亿美元至4.7亿美元之间,表明同比增长3%至9%。

  • 该公司将捆绑支付系统视为有效控制和管理市场的必要举措。实施只能在 2026 年或之后进行。

  • 对于ReNU产品,ORGO预计将在5月底之前完成数据分析,并在8月初与美国食品药品管理局举行会议。他们预计将在9月份公布结果。

  • 根据一项或两项研究的批准要求,它们的目标是在26年第二季度(两项研究)或25年(一项研究)提交BLA,相应的预计批准和商业化分别在27年或26年的第二季度。

More details: Organogenesis IR

更多详情: 器官发生红外

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发